International journal of hematology · 2023
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Наблюдательное исследованиеМногоцентровое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Usuki Kensuke, Ohtake Shigeki, Honda Sumihisa, Matsuda Mitsuhiro, Wakita Atsushi, Nawa Yuichiro, Takase Ken, Maeda Akio, Sezaki Nobuo, Yokoyama Hisayuki, Takada Satoru, Hirano Daiki, Tomikawa Tatsuki, Sumi Masahiko, Yano Shingo, Handa Hiroshi, Ota Shuichi, Fujita Hiroyuki, Fujimaki Katsumichi, Mugitani Atsuko, Kojima Kensuke, Kajiguchi Tomohiro, Fujimoto Ko, Asou Norio, Usui Noriko, Ishikawa Yuichi, Katsumi Akira, Matsumura Itaru, Miyazaki Yasushi, Kiyoi Hitoshi
Аннотация
We conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan. From August 2011 to January 2016, we enrolled 6568 patients. Herein, we report the results for MDS (n = 2747) and CMML (n = 182). The percentage of patients aged 65 years or older was 79.5% for MDS and 79.7% for CMML. The estimated overall survival (OS) rate and cumulative incidence of AML evolution at 5 years were 32.3% (95% confidence interval: 30.2-34.5%) and 25.7% (23.9-27.6%) for MDS, and 15.0% (8.9-22.7%) and 39.4% (31.1-47.6%) for CMML. Both diseases were more common in men. The most common treatment for MDS was azacitidine, which was used in 45.4% of higher-risk and 12.7% of lower-risk MDS patients. The 5-year OS rate after treatment with azacitidine was 12.1% (9.5-15.1%) for of higher-risk MDS patients and 33.9% (25.6-42.4%) for lower-risk patients. The second most common treatment was erythropoiesis-stimulating agents, given to just 20% of lower-risk patients. This is the first paper presenting large-scale, Japanese data on survival and clinical characteristics in patients with MDS and CMML.